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      Introduction: Since its introduction in 1964, hemodialysis has become one of the main 
modalities for the treatment of end-stage renal disease (ESRD). Central venous catheter 
(CVC) has become an important means in providing vascular access for hemodialysis 
treatment. Due to its nature as an indwelling catheter, there is an increased risk of developing 
catheter-related bloodstream infections (CRBSI). Hence, identifications of relevant risk 
factors for CRBSI development has become the paramount objective of this research 
endeavour. 
     Objectives: The aims of this study were to determine the prevalence of catheter-related 
bloodstream infections (CRBSI) among hemodialysis patient at Hospital Universiti Sains 
Malaysia using temporary central venous catheter and its associated factors, also to identify 
the commonest microorganism isolated and its antibiotic sensitivity. 
 
     Methodology: This is a retrospective cohort study involving a review of the medical 
records of 116 ESRD Hospital USM (HUSM) on haemodialysis via CVC from 1st January 
2013 until 31st October 2014. Relevant details on the identified CRBSI risk factors such as 
age, gender, comorbidities, length of hospital stay prior to CVC insertion, duration of 
catheterization, HbA1c level, catheter insertion sites, haemoglobin level, WBC, serum 
albumin and urea levels, and aetiologies of End Stage Renal Disease (ESRD) were collected. 
The data was analysed using multiple logistic regression and the probability equation for 
predicting the development of CRBSI was computed. Level of significance was fixed at 0.05. 
 
     Results: : The prevalence of CRBSI is 19% (95% CI 11.9,26.1) with CRBSI rate of 3.5 
bacteremia per 1000 catheter days. S. aureus (including MRSA) are the main microorganisms 
isolated among CRBSI cases (45.4%), followed by P.aeruginosa (22.7%) and others. Most of 
microbial isolates are susceptible to at least one type of antibiotics. Three significant risk 
factors for CRBSI were identified from multiple logistic regression analysis; duration of 
hospital admission before catheterization (adjusted OR:1.118 (95% CI: 1.030, 92.805),  p 
value = 0.004),  duration of catheterization in days (adjusted OR: 0.965 (95% CI 0.939, 
0.992), p value = 0.005) and HbA1c levels ( i) HbA1c 6.6-8.0% (adjusted OR: 1.143 (95% 
CI: 0.249,5.247), p value = 0.849) and ii) HbA1c ≥8.0% (adjusted OR: 5.613 (95% CI 1.023, 
30.792), p value = 0.047). 
 
      Conclusion: The prevalence and CRBSI rate are comparable with other studies. Gram-
positive cocci are still the predominant species isolated from HD subjects with CVC. Length 
of hospital stay prior to catheter insertion, duration of catheterization and HbA1c level were 
significant risk factors identified for CRBSI. 
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ABSTRAK 
 JANGKITAN  ALIRAN DARAH DISEBABKAN KATETER DIKALANGAN 
PESAKIT GINJAL TAHAP AKHIR YANG MENJALANI HEMODIALISIS 
MENGGUNAKAN KATETER VENA PUSAT SEMENTARA  DI HUSM: 
KAJIAN RETROSPEKTIF KOHORT DATA  TERKUMPUL SELAMA  2 
TAHUN. 
 
Pengenalan: Semenjak diperkenalkan pada tahun 1964, hemodialisis telah menjadi 
salah satu kaedah rawatan untuk pesakit ginjal tahap akhir. Kateter vena pusat telah 
menjadi salah satu cara untuk penyediaan akses salur darah bagi mencapai matlamat 
rawatan hemodialisis. Disebabkan ciri-ciri kateter vena pusat sebagai kateter yang 
menembusi kulit, terdapat peningkatan dari segi kadar jangkitan kuman disebabkan 
kateter jenis ini. Oleh itu, pengenalpastian faktor-faktor risiko yang relevan yang 
menyebabkan berlakunya jangkitan aliran darah disebabkan penggunaan kateter vena 
pusat (JADDKVP) adalah menjadi matlamat kajian ini. 
Metodologi: Ini adalah kajian retrospektif kohort yang melibatkan  rekod perubatan   
116 pesakit ginjal tahap akhir yang menjalani hemodialisis di Hospital USM 
(HUSM) menggunakan kateter vena pusat bermula daripada 1 Januari 2013 sehingga 
31 Oktober 2014. Maklumat-maklumat yang relevan berkenaan faktor-faktor risiko  
JADDKVP seperti usia pesakit, jantina, status penyakit lain, tempoh masa berada di 
hospital sebelum kateter dimasukkan, selang tempoh kateter digunakan, paras 
HbA1c, lokasi kateter dimasukkan, paras hemoglobin, sel darah putih, paras albumin 
dan urea dalam serum darah dan penyebab penyakit ginjal tahap akhir. Data 
kemudiannya dianalisis dengan regresi logistik berganda dan persamaan 
kebarangkalian yang memberi ramalan berlakunya jangkitan aliran darah disebabkan 
kateter dihasilkan. Paras kepentingan ditetapkan pada 0.05. 
Keputusan: Prevalens JADDKVP adalah 19.0% (95% selang keyakinan: 11.9,26.1) 
manakala kadar JADDKVP adalah 3.5 kes bakterimia bagi setiap 1000 kateter-hari. 
S.aureus (termasuk jenis MRSA) merupakan mikrorganisma utama yang didapati di 
kalangan kes JADDKVP (45.4%), diikuti P.aeruginosa (22.7%) dan lain- lain. 
Kebanyakan mikrorganisma yang diasingkan adalah sensitif sekurang-kurangnya 
terhadap satu jenis antibiotik. Terdapat tiga faktor risiko ketara yang menyebabkan 
JADDK ditemui melalui analisis regresi logistic berganda: panjang tempoh 
kemasukan di hospital sebelum kateter dimasukkan (nisbah kemungkinan terselaras: 
1.118 (95% selang keyakinan: 1.030, 92.805) nilai p = 0.004),  selang tempoh kateter 
digunakan (dalam unit hari) (nisbah kemungkinan terselaras: 0.965 (95% selang 
keyakinan: 0.939, 0.992), nilai p = 0.005) dan paras HbA1c ( i) HbA1c 6.6-8.0% 
(nisbah kemungkinan terselaras: 1.143 (95% selang keyakinan: 0.249,5.247), nilai p 
= 0.849) and ii) HbA1c ≥8.0% (nisbah kemungkinan terselaras: 5.613 (95% selang 
keyakinan 1.023, 30.792), nilai p = 0.047). 
Rumusan: Prevalens dan kadar JADDKVP adalah bersamaan seperti anggaran 
kajian-kajian yang lain. Bakteria kumpulan ‘cocci’ yang positif-Gram masih 
merupakan jenis utama bakteria yang didapati dikalangan kes-kes JADDKVP. 
Tempoh masa kemasukan ke hospital sebelum kateter dimasukkan, jangka masa 
kateter dan paras HbA1c telah dikenalpasti sebagai factor yang ketara menyebabkan 
JADDKVP.  
 
 
 
  
ABSTRACT 
 
CATHETER-RELATED BLOOD STREAM INFECTION (CRBSI) IN ESRD 
SUBJECTS UNDERGOING HAEMODIALYSIS VIA TEMPORARY 
CENTRAL VENOUS CATHETER AT  HUSM: A RETROSPECTIVE 
COHORT REVIEW OF 2 YEAR DATA 
 
Introduction: Since its introduction in 1964, haemodialysis has become one of the 
main modalities for the treatment of end-stage renal disease (ESRD). Central venous 
catheter (CVC) has become an important means in providing vascular access for 
haemodialysis treatment. Due to its nature as an indwelling catheter, there is an 
increased risk of developing catheter-related bloodstream infections (CRBSI). 
Hence, identifications of relevant risk factors for CRBSI development has become 
the paramount objective of this research endeavour. 
Methodology: This is a retrospective cohort study involving a review of the medical 
records of 116 ESRD Hospital USM (HUSM) on haemodialysis via CVC from 1st 
January 2013 until 31st October 2014. Relevant details on the identified CRBSI risk 
factors such as age, gender, comorbidities, length of hospital stay prior to CVC 
insertion, duration of catheterization, HbA1c level, catheter insertion sites, 
haemoglobin level, WBC, serum albumin and urea levels, and aetiologies of End 
Stage Renal Disease (ESRD) were collected. The data was analysed using multiple 
logistic regression and the probability equation for predicting the development of 
CRBSI was computed. Level of significance was fixed at 0.05. 
Results: The prevalence of CRBSI is 19% (95% CI 11.9,26.1) with CRBSI rate of 
3.5 bacteraemia per 1000 catheter days. S. aureus (including MRSA) are the main 
microorganisms isolated among CRBSI cases (45.4%), followed by P.aeruginosa 
(22.7%) and others. Most of microbial isolates are susceptible to at least one type of 
antibiotics. Three significant risk factors for CRBSI were identified from multiple 
logistic regression analysis; duration of hospital admission before catheterization 
(adjusted OR:1.118 (95% CI: 1.030, 92.805),  p value = 0.004),  duration of 
catheterization in days (adjusted OR: 0.965 (95% CI 0.939, 0.992), p value = 0.005) 
and HbA1c levels ( i) HbA1c 6.6-8.0% (adjusted OR: 1.143 (95% CI: 0.249,5.247), 
p value = 0.849) and ii) HbA1c ≥8.0% (adjusted OR: 5.613 (95% CI 1.023, 30.792), 
p value = 0.047). 
Conclusion: The prevalence and CRBSI rate are comparable with other studies. 
Gram-positive cocci are still the predominant species isolated from HD subjects with 
CVC. Length of hospital stay prior to catheter insertion, duration of catheterization 
and HbA1c level were significant risk factors identified for CRBSI. 
 
 
 
 
 
 
 
 
 
 
CHAPTER ONE 
INTRODUCTION 
 
1.1 THE USE AND ECONOMIC BURDEN OF HAEMODIALYSIS 
THERAPY: A GLOBAL COMPARISON  
Dialysis therapy was elementarily initiated in Malaysia in 1964, primarily for 
the treatment of acute renal failure (Lim et al., 2008). This was subsequently 
followed by the institution of chronic haemodialysis in 1969, the first renal 
transplant in mid-1970s and continuous ambulatory peritoneal dialysis in 1981 (Lim 
et al. 2008). Since then, the epidemiological scene of the uptake of renal replacement 
therapy (RRT) has drastically increased; 50 patients on haemodialysis in 1980 
compared to nearly 15000 haemodialysis patients in 2006 (Lim et al. 2008). Besides, 
there’s also a hike in the haemodialysis acceptance rate which is about 3 per million 
population in 1981 to 116 per million population in 2006 (Lim et al. 2008). Apart 
from that, there is a large difference with respect to prevalence rate of haemodialysis 
usage between 1980 and 2006; 4 per million and 550 per million, respectively (Lim 
et al.  2008).  
Based on the 21st report of the Malaysian dialysis and transplant registry 
2013, the prevalence rate of dialysis is 1065 per million populations in 2013 
(Malaysian Society of Nephrology 2013), which is about twice the prevalence rate in 
2008. This can be translated into a doubling of dialysis acceptance rate from 112 per 
million population in 2004 to 223 per million population in 2012 (Malaysian Society 
of Nephrology 2013). Therefore, the increased need for haemodialysis may result in 
further requirements for permanent and temporary vascular access, leading to a much 
higher occurrence of catheter-related complications such as thrombosis and 
infections. 
Besides, the raising prevalence rate of dialysis also occurred in other 
populations. For instance, a study by Cusumano et al. (2013) also demonstrated an 
increase in the prevalence rate of  ESRD patients requiring renal replacement therapy 
(RRT) in Latin America from 119 patients per million population in 1991 to 568 
patients per population in 2008, with the highest reported prevalence rates in Puerto 
Rico (1170 patients per million population), Uruguay (1079 patients per million 
population) and Chile (1036 patients per million population) . Haemodialysis is the 
primary mode of RRT (342 patients per million population) followed by peritoneal 
dialysis (119 patients per million population) and finally vascular grafts (106 patients 
per million) (Cusumano et al., 2013). Apart from that, based on the data provided by 
the Korean Insan Prof. Byung-Suk Min Memorial ESRD Patient Registry, the 
prevalence rate of dialysis among ESRD patients in Korea is 1010 patients per 
million population (Jin et al. 2015). The same trend is also observed among Chinese 
ESRD patients residing in Beijing; a raising prevalence rate of haemodialysis was 
observed which is from 94 patients per million population in 2007 to 147.3 patients 
per million population in 2010 (Zuo et al. 2013). However, the current dialysis 
treatment rate among Sub Saharan African countries is still below 20 patients per 
million population, reflecting the lack of reliable renal registries and inadequate 
nephrology resources (funding, poor facilities and insufficient support) (Naicker 
2013). With respect to those of Caucasian origin, the last report from the Italian 
Registry of Dialysis and Transplant (RIDT) showed that the prevalence rate of 
dialysis among Italian population with ESRD is 788 patients per million population 
(Roggeri et al., 2014). In Ukraine, the latest estimate of prevalence rate of dialysis is 
96.6 per million population (Kolesynk et al., 2014). Hence, from all these 
observations we could conclude that the prevalence rate of dialysis is increasing 
worldwide. The prevalence rate of haemodialysis in Malaysia can be considered to 
be relatively lower than other countries, attributable to better preventive measures 
and provision of healthcare services adopted by the Malaysian government. 
Nevertheless, our attention on preventive measures should not be deviated, as the 
number of ESRD patients requiring haemodialysis is increasing at an alarming rate 
in our locality. Further actions such as intensive patient education, secondary 
prevention programmes in retarding the kidney disease progression are required to 
curb and eventually reverse this worrying trend. 
The cost of haemodialysis has become a constant source of financial burden 
to ESRD patients. With respect to Malaysian context, the estimates of the cost of 
haemodialysis are only provided by three studies. Based on the estimate provided by 
a multicentre study involving 44 haemodialysis and 11 continuous ambulatory 
peritoneal dialysis (CAPD) centres by Hooi et al. (2005), the cost of haemodialysis 
ranged from RM 79.61 to RM475.79 per haemodialysis session and the mean cost is 
RM 169 per session. This is comparatively higher considering CAPD treatment 
which was estimated ranging between RM 1400 to RM 3200 per patient month 
(mean RM 2186 per patient month) (Hooi et al., 2005). Besides, the cost per life year 
saved is much higher with haemodialysis (RM 33642) than with CAPD (RM 31635). 
This reflects a sudden drop in the cost-effectiveness of haemodialysis which was 
found to be the highest (haemodialysis centre: RM 21620 per life year saved, home 
dialysis: RM 23375 per life year saved) compared to CAPD (RM 30469 per life year 
saved) and IPD (RM 36016 per life year saved) in 1999 (Lim et al., 1999). The 
findings on CAPD made by Morad et al. (2005) would not be used as a comparison 
in here and thus further discussed since dubious and less comprehensive method was 
employed for cost calculation (which was only based on basic cost whilst other 
indirect costs such as transportation, loss of productivity and costs due to 
complications and extra medication are not included in the analysis).  
In other countries around the globe, the cost of haemodialysis is substantially 
high. In a report by de Abreu et al., (2013), the total mean cost of maintenance 
haemodialysis per patient year at Sao Paolo, Brazil is at a staggering amount of US$ 
28570. Besides, according to USRDS 2012 annual report, the cost of haemodialysis 
per patient per annum was approximately USD 66750 (USRDS 2012). These data 
are further corroborated by Saran and Sabry (2012) who showed that the total 
average cost of each haemodialysis session is approximately around USD297 (1,141 
Saudi Riyal). In addition, Ranasinghe et al. (2011) showed that the cost of each 
dialysis session in Sri Lanka is LKR  6377 (equivalent to USD 56). The exorbitant 
cost of haemodialysis has thus been summarized in a review by Karopadi et al. 
(2013) who demonstrated that HD treatment is between the range of 1.25 and 2.35 
times of peritoneal dialysis cost in most developed countries. The authors also 
commended the Malaysian government’s efforts in reducing the cost for PD by 
waiving import duty for CAPD (Karopadi et al., 2013). The haemodialysis treatment 
cost will also be escalated if catheter-related complications occur, as such 
exacerbates the financial impact on the ESRD patients. Therefore, it is imperative 
that effective preventive measures be implemented and complications can be 
avoided. These can be achieved if the putative risk factors for each complication are 
fully known.   
 
 
1.2 HAEMODIALYSIS CATHETERS AND INFECTIONS 
 Since the past two decades, the duration of catheter use and placement rates 
have surged (USRDS 2012). Around 80% of patients in North America received 
their weekly haemodialysis via catheters, with a catheter use rate of 50% 4 months 
after the initiation of haemodialysis (Canadian Organ Replacement Register 2012, 
USRDS 2012). Delayed in AVF creation, time requirement for access maturation, 
frequent complication and need for new access site become a common reason for 
temporary catheter insertion. As a result, infection has now become the commonest 
cause of morbidity and second most common cause of mortality among HD 
recipients, with sepsis-associated mortality rate of more than 100 times than the 
general population (Schaubel et al., 2000, Sarnak and Jaber, 2000). Besides, it was 
estimated that 30% of patients using central venous access for haemodialysis will 
experience at least a single bacteraemia or septic episode per year (Ishani et al., 
2005). This is further supported by the findings of Astor et al. (2005) and Hoen et al.  
(1998) who revealed catheter use for haemodialysis access has higher risk of 
bacteraemia than those via arteriovenous fistula (AVF) (estimated relative risk and 
hazard ratio are 7.6 and 1.5, respectively). Consequently, CRBSI result in longer 
ICU stay and higher cost to the healthcare sector (estimated between USD 3000 to 
USD 56167 per episode), making its prevention imperative to ensure and maximize 
the safety of HD patients (Palomar et al., 2013). 
 In spite of the institution of well-documented effective prophylactic schemes 
and the ubiquitous disseminations of clinical practice guidelines for the prevention of 
vascular access-related infections, the rates of catheter-related infections continue to 
be significantly high (Lok and Foley, 2013). Pronovost and colleagues (2006) have 
identified five evidence-based procedures which will greatly cut the risk of CRBSI 
when implemented properly; good hand washing practices, the utilization of full-
barrier provision during the insertion of CVCs, the use of chlorhexidine during 
cleaning of the skin, avoidance of femoral sites for CVC insertion and prompt 
removal of unneeded catheters. This evidence-based CRBSI prevention protocol has 
been demonstrated to cut the median rate of CRBSI from 2.7 per 1000 days to 0 case 
per 1000 days (Pronovost et al. 2006), a finding that has been further corroborated 
by Peredo et al.  (2010) who showed an absolute relative risk reduction (ARR) of 
0.74 ( (95% CI 0.20 , 0.84) , p value = 0.015). Hence, the identification of risks 
factors and contexts which posed the HD patients at high infection risks is 
paramount so that further improvements can be made to the existing protocols for the 
prevention of CRBSI. 
1.3 TYPES OF HAEMODIALYSIS CATHETERS 
 In general, there are two major types of catheters used for haemodialysis; 
non-tunnelled or temporary and tunnelled or permanent catheters. The non-tunnelled 
catheters are meant for short term use and are made of rigid materials like hard 
polyurethane or polyvinyl with tapered end to permit quick percutaneous insertion 
via Saldinger technique. Nevertheless, the newer generation of this catheter type 
(like the ones made of silicone) are usually made of softer materials with adjustable 
cannula that can be utilized to steady the catheter for insertion. Besides, they can also 
provide a higher rate of blood flow (400 ml/ min or greater vs 200 to 250 ml / min) 
compared to the previous model. These non-tunnelled catheters are devoid of 
retention cuffs and therefore should not be inserted into a subcutaneous tunnel. They 
are in different shapes (curved or straight) which enable them to be easily inserted at 
required insertion sites (femoral, internal jugular etc). The usual post-insertion 
lifetime for this type of catheters is usually between several days to several weeks. 
 On the other hand, tunnelled catheters have Dacron cuffs that can be adjusted 
and positioned into subcutaneous tunnels. The cuff functions as a fibrotic shield, 
preventing the migration of bacteria from the surrounding skin tissues into the 
bloodstream. Tunnelled catheters are usually made of soft polyurethane and usually 
introduced into the skin via a peelable sheath or trocar. The first original brand of 
this catheter, PermCath®, was marketed by Quinton Instrument Company which was 
based at Salt Lake City, Utah, USA. A new design subsequently superseded the large 
oval, two-lumen PermCath®; Vas Cath™ and Tesio™. These new designs were then 
proven to be more effective than PermCath® in preventing the complications related 
to the use of transcutaneous devices. Figure 1.1 and 1.2 represent the schematics of a 
cuffed tunnelled catheters: 
 
 
Figure 1.1: The schematic representation of a cuffed tunnelled catheter 
 
 
Figure 1.2: The transverse view of three commonly used cuffed tunnelled catheters 
   (Schwab and Beathard 1999, with permission) 
 CHAPTER TWO 
LITERATURE REVIEW 
 
2.1 THE PATHOGENESIS AND DIAGNOSIS OF CRBSI 
 According to Trautner and Darouiche (2004), there are four primary routes 
by which catheters maybe contaminated by the infectious agents: 
• Colonization by migrating skin microorganisms from sites of insertion into 
catheter tracts or along catheter surfaces which results in catheter tip 
colonization. 
• Direct contaminants: fluids and unhygienic hand procedures/contacts which 
result in catheter or catheter hub contaminations 
• Haematogenous dissemination of infections from other foci which is 
subsequently sown at the catheter site (uncommon) 
• Contamination of infusate such as heparin flush (rare). 
Among the four routes above, the first two are undoubtedly the most important. Hub 
contamination and skin sites colonization can be attributed to endogenous flora on 
the patient’s skin or exogenous flora that are transferred from the healthcare’s 
workers hands to the patient’s skin or catheter hub during catheter insertion. 
Nevertheless, there are two main differences in terms of microbial migratory patterns 
depending upon where the initial contaminants occur; those which gain entry 
through the skin insertion sites will usually migrate upon the surface of the catheter 
whilst those microorganisms which contaminated the catheter hub will tend to 
migrate on the luminal surface of the catheters (Crnich and Maki 2002, Raad and 
Hanna 2002). The types of endogenous flora that are usually found to reach the 
catheter site from the skin sites are coagulase-negative staphylococci and S. aureus 
whilst those which generally contaminated the catheter hubs are Stenotrophomonas 
sp, Pseudomonas sp, enterococci and Candida sp. 
 On the contrary, haematogenous spread of flora from remote sites such as the 
urinary tract is more of mechanistic conjectures than a possible certainty. Thus, the 
removal of catheters may not be necessary after well-recorded infections from 
secondary sites (Raad and Bodey 1992, Anaissie et al. 1995). Even though sepsis 
associated with contaminated infusates such as parenteral nutrition and lipid 
solutions has been well-documented, these occurrences can be considered rare with 
different pathological mechanisms that are beyond the scopes of this review. 
However, a recent study by Turpin et al. (2014) showed that the administration of 
parenteral nutrition via ready-to-use-three-chamber bag (MCB) was associated with 
the lowest hazard of CRBSI compared to administration via single bottle (SB) 
(hazard ratio: 2.53 (95% CI 1.66,3.86), p value <0.05) and hospital compounded 
admixture (CPN). Besides, they also found out that the use of MCB incurred the 
lowest hospitalization cost and thus the most cost-effective method in preventing 
CRBSI (Turpin et al. 2014). 
 The duration of time from the first insertion of central venous catheters to the 
first appearance of bacteria-embedded biofilms can be variable. Passerini and co-
workers (1992) demonstrated using electron microscopy that biofilm formation can 
occur as early as 24 hours post insertion of central venous catheters. Nevertheless, 
the colonization of catheter’s external surfaces is predominant in short-term 
indwelling catheters that are placed for less than 10 days whilst the colonization of 
intraluminal surfaces of the catheters is only prevalent after the introduction of long-
term indwelling catheters such as subcutaneous ports, peripherally-inserted central 
catheters (PICC) and tunnelled CVC and this may occur only after 30 days following 
the insertion of such catheters (Raad et al. 1993). However, the probability of such 
catheter colonization will culminate in overt bloodstream infections is quantitatively 
dependent upon the number of microorganisms isolated from the catheter surfaces by 
roll-plated methods and the dissimilarities with respect to the pathogenesis of CRBSI 
between the usage of short-term and long-term catheters may result in the differences 
of optimal preventive options for both types of CRBSI. 
 There are several well-reported metastatic complications of CRBSI. In a 
review by Lok and Mokrzycki (2011), the followings are the most frequently 
encountered metastatic complications of CRBSI: 
Table 2.1 : Metastatic complications of CRBSI (Lok and Mokrzycki 2011) 
CRBSI metastatic complications Prevalence (%) 
Endocarditis 3-7 
Death 6-34 
Osteomyelitis 1.5-15 
Septic arthritis 2-5 
Septic emboli (eg brain) 1-2 
Other abscesses 1.5 
Septic pulmonary emboli 0.4 
Large atrial thrombi  rare (<0.1) 
 
 
 
 The diagnosis of CRBSI is currently based upon satisfying one of the 
following 3 criteria (Mermel et al. 2009): 
i) Identical microorganisms isolated from blood culture and semi-quantitative (roll-
plate) culture (>15 colony-forming units (cfu) ) or quantitative (sonication) broth 
culture (>102 cfu)  of the tips of catheters 
ii) Similar microorganisms isolated from blood culture obtained through 
venoepuncture and catheter lumen, provided microbial growth were detected sooner 
(2 hours or more incubation time) in the latter sample. [differential time to positivity 
method] 
iii) Same microorganism isolates detected from both percutaneous blood samples 
and blood obtained from catheter hub, with 3-fold higher colony-forming units in the 
latter. [quantitative blood culture method] 
Nevertheless, there have been a few criticisms have been hurled upon the use of 
differential time to positivity (DTP) as a mean of diagnosing CRBSI. Kaasch et al. 
(2013) observed that DTP does not reliably predict CRBSI secondary to S.aureus  in 
routine clinical setting (positive predictive value (PPV) of 0.46 (95% CI: 0.28,0.65) 
and negative predictive value (NPV) of 0.70 (95% CI: 0.58,0.80) ). This finding 
contradicts the observations made by Blot et al. (1999) who demonstrated that DTP 
is an easy and reliable diagnostic method for CRBSI confirmation among cancer 
patients with CVC. Hence, both methods / criteria are now regarded as acceptable 
standards for diagnosing CRBSI (Mermel et al., 2009).  
2.2 THE PRINCIPAL MICROORGANISMS IMPLICATED FOR CRBSI  
 According to Saad (1999) and Lok et al.  (2003), the microorganisms that are 
most commonly isolated from catheter sites are Gram-positive bacteria, with 
methilline-sensitive S.aureus  is the commonest (21 to 43%) followed by methicillin-
resistant S.aureus (MRSA). With respect to Gram-negative species, Pseudomonas 
and Stenotrophomonas species are the main microorganism isolates for the majority 
of CRBSI cases (Mokrzycki et al. 2006).  Nevertheless, the primary types of 
microorganism isolated may vary from one study to another. For instance, Patil et al. 
(2011) reported that the primary isolates identified from catheter tips and blood 
cultures are S.epidermidis (45%), followed by S.haemolyticus and S.aureus (15% 
each). Apart from that, there are also differences in the types of microorganism 
isolates between those developing early-CRBSI (defined as development of CRBSI 
in less than 24 hours after the removal of colonized catheters) and late-CRBSI 
(CRBSI develops 24 hours after the removal of colonized catheters). A study by 
Guembe et al. (2014) demonstrated significantly higher number of coagulase-
negative staphylococci (CONS) in early-CRBSI than late-CRBSI cases, whilst 
MRSA isolates were significantly found in greater numbers in late-CRBSI than 
early-CRBSI. Therefore, this lends evidential supports to the variability of the types 
of microorganisms primarily implicated for CRBSI.  
2.3 THE THERAPEUTIC MANAGEMENT OF CRBSI 
 According to the guideline produced by the Infectious Disease Society of 
America (IDSA) for the diagnosis and management of intravascular catheter-related 
infections in 2009, penicillinase-resistant penicillin such as nafcillin or oxacillin 
should be given to methacillin susceptible staphylococci (Mermel et al. 2009). 
Cefazolin 2g given every 8 hours or vancomycin 15mg/kg twice daily (12 hourly) 
can be reserved as an alternative agent to penicillinase-resistant penicillin (Mermel et 
al., 2009).  For MRSA, vancomycin (using the same dose as above), daptomycin (6-
8mg/kg/day) or linezolid are the recommended treatments for CRBSI (Mermel et al., 
2009). For Gram negative bacilli, on the other hand, the choice of antibiotics should 
be guided by the local antimicrobial susceptibility data and CRBSI severity (Mermel 
et al., 2009). Based on the recent report on local susceptibility data by Abdul Gafoor 
et al. (2014), intravenous vancomycin and ceftazidime (Fortum®) or cefepime are 
the antibiotics of choice since they provide the greatest coverage for all types of 
bacteria (Gram-positive and negative alike, both MRSA and methicillin-sensitive 
S.aureus (MSSA) ) implicated for CRBSI. Besides, the catheter should always be 
removed if CRBSI is found to be due to S.aureus, Pseudomonas sp. or Candida sp. 
and this should be replaced with a new temporary catheter (Mermel et al., 2009). If 
catheter removal is not indicated due to the absence of metastatic infection or 
resolution of symptoms 2-3 days after the start of antibiotics, the catheter can be left 
in place with a concurrent adjunctive use of antibiotic lock administered after the end 
of each dialysis sessions (Mermel et al., 2009).    
  Nevertheless, in a much more recent systematic review and management of 
haemodialysis catheter-related infection, Aslam et al. (2014) recommended that 
treatments with either guidewire exchange or antibiotic lock solution provide a more 
superior treatment success rate compared to systemic antibiotic alone (Antibotic lock 
solution: OR:2.08 (95% CI, 1.25 to 3.45), p value <0.010; guidewire exchange: 
OR:2.88 (95% CI: 1.82 , 4.55), p value <0.001). Besides, the authors also found that 
the proportions of cured cases were highest in those infected with CONS, followed 
by gram-negative rods and S.aureus (Aslam et al., 2014). Furthermore, guidewire 
exchange was found to be the most effective modality in resolving S.aureus-
associated CRBSI when comparisons were made against systemic antibiotic use   
OR:3.33 (95% CI: 1.17,  9.46) p value = 0.020) or antibiotic lock solution (OR:4.72 
(95% CI: 1.79, 12.46)p value = 0.002). Hence, guidewire exchange has now become 
the preferential modality over systemic antibiotic use or antibiotic lock solution 
alone for the therapeutic management of CRBSI. 
 2.4 A REVIEW OF RISK FACTORS FOR CATHETER-RELATED 
BLOODSTREAM INFECTIONS 
 The risk factors for CRBSI can be classified into four major groups; host 
related factors, catheter-related factors, pathogen-related factors and haemodialysis-
related factors. For the first one, older age has been associated with raising risk of 
CRBSI (mean age in bacteraemia vs non bacteraemia subjects:  64.6 years vs 59.8 
years , p value <0.05) (Jean et al. 2002).  
Besides that, impairment of immunity due to neutrophil and monocyte 
dysfunctions, derangement in T-cell and humoral response activation secondary to 
uraemia, hyperparathyroidism and excessive iron load may also be incriminated for 
CRBSI occurrence (Jaber 2005). Moreover, the coexisting diabetes mellitus (39% 
(CRBSI) vs 18% (non-CRBSI) , p value<0.001), low haemoglobin (mean serum Hb 
in BSI vs non BSI patients: 10.51g/dL vs 11.14 g/dL, p value <0.001)  and 
hypoalbuminaemia (34.3 g/dL (CRBSI)  vs 36.9 g/dL (non-CRBSI), p value < 
0.001) may also induce CRBSI development in subjects who received haemodialysis 
via CVC (Fysaraki et al. 2013, Tanriover et al. 2000). Apart from those factors 
above, previous hospitalization and history of previous bacteraemia also pose 
subjects who opt for CVC as a mean of haemodialysis access  (Tokars et al., 2001). 
Nevertheless, all risk factors above required further investigation in our local setting 
since the effect sizes (relative risk, odds ratio) obtained from the above studies are 
still inconclusive which may negate the existence of clinical significance  (for 
instance, the difference in haemoglobin concentration between CRBSI and non 
CRBSI subjects are small (mean difference: 0.6 g /dL) in Fysaraki et al.  (2013) 
study). 
For catheter-associated risk factors, duration of catheter use has been singled out 
as one of the most important catheter-associated risk factors. Lemaire and colleagues 
(2009) demonstrated that the use of permanent dual catheter  for haemodialysis 
exceeding 90 days increased the odds of CRBSI by 1.85 (95% CI 1.35, 2.55; p value 
<0.05). Their findings were further corroborated by those of Jean and associates 
(2002) who showed longer duration of  dialysis catheter use in CRBSI subjects than 
non CRBSI subjects (mean days of catheter use: 648 days 296 days, p value t-test 
<0.001). Apart from that, sites of catheter insertion have been found to be a 
significant risk factor for CRBSI. For instance, Kairaitis and Gottlieb (1999) found 
that CRBSI occurs more common if internal jugular vein was chosen as the insertion 
site than subclavian vein (. This is supported by Develter  et al. (2005)  who showed 
79.8% increase in risk of developing catheter-related bacteraemia if the catheter was 
placed in right internal jugular vein than other sites of insertion. However their 
findings were not statistically significant (95% CI 0.983,3.625; p value =0.068). 
Nevertheless, the generalizability of the findings from both studies are hampered by 
2 factors; 1)  the studies only utilized subjects using tunnelled catheters, 2) the use of 
subclavian vein predisposes subjects to a greater risk of  catheter-related central 
venous stenosis. As a result, the routine use of subclavian vein as a haemodialysis 
access site is thus contraindicated and further investigations are required to ascertain 
the benefits associated with it. 
Besides, prompt withdrawal of catheter after a positive test result for isolates on 
catheter tips is associated with low risk (around 4.1%) of developing late CRBSI 
(Guembe et al. 2014). Interestingly, despite the low risk of developing late-CRBSI, 
it is still associated with high rate of crude mortality (Guembe et al. 2014). Hence, it 
is imperative that catheter should cared for and taken out even before colonization 
occurs. Besides, the techniques used for the insertion of catheter and types of sterile 
barrier precautions used may also influence the rate of CRBSI. For instance, Haga et 
al. (2013) found that the use of direct puncture for catheter insertion and maximal 
sterile barrier precaution (MSBP) resulted in significant reductions of CRBSI rate 
per 1000 catheter days when compared to Seldinger method for catheter insertion 
and standard sterile barrier precaution (SSBP) methods, respectively (p values = 
0.025 and 0.030, respectively). Apart from that, the use of antimicrobial or antiseptic 
coating of catheters (eg. antibiotic lock therapy) may also decrease the risk of CRBSI 
(Shah et al. 2013). Nevertheless, the success rate in preventing CRBSI is variable 
which may be due to the inefficacy of antibiotic locking solution to kill microbes in a 
biofilm. This is further corroborated by Kropec et al. (1993) and Ramirez de 
Arellano et al. (1994), both demonstrated that a 100 to 1000-fold higher antibiotic 
concentrations were required to eradicate bacteria in biofilms (sessile bacteria) than 
free-floating bacteria (planktonic bacteria). 
With regard to pathogen-related risk factors, S.aureus nasal carriage has been 
studied the most. Again, it was Jean and associates (2002) who first successfully 
demonstrated the relationship between the presence of S.aureus nasal colonization 
and CRBSI. They observed a shorter median time for catheter survival before the 
occurrence of first bacteraemia episode in those with positive S.aureus nasal carriage 
than those without S. aureus nasal colonization (median time to first catheter-
associated bacteraemia: 128. days vs 209.5 days, p value<0.001). Besides that, a 
short treatment with mupirocin ointment (<5 days) has been shown to successfully 
eradicate S.aureus nasal carriage which results in a reduction of CRBSI caused by 
S.aureus (Betjes 2011). Therefore, these evidences consolidate the roles of S.aureus 
nasal carriage in CRBSI. Besides that, antibiotic resistance pattern, bacterial 
virulence, and bacterial propensity for biofilm formation also played great roles in 
the occurrence of CRBSI.  These factors would not be reviewed since they will not 
be evaluated in this study. 
 Lastly, with respect to haemodialysis-related factors, haemodialysis adequacy 
parameters were firstly identified as significant risk factors for CRBSI by 
Bloembergen et al. (1996). They showed that a 5% increase in urea reduction ratio 
(URR) and 0.1 increase in kt/V are significantly associated with  12.4% and 9% 
reductions in the risk of developing CRBSI.  However, their findings were negated 
by the observations made by the investigators of HEMO study who established the 
lack of association of between CRBSI and haemodialysis adequacy parameters. They 
also did not find any significant association between CRBSI and  types of dialysis 
membrane flux (high or low flux) (Allon et al., 2003). These conflicting pieces of 
evidence requires further investigation to place the roles of both haemodialysis 
adequacy parameters and types of dialysis membrane flux as risk factors for CRBSI 
on a firmer footing. 
 
 
 
 
 
 
2.5 RATIONALE OF THE STUDY 
Despite many prior studies have investigated and identified nearly all major 
CRBSI determinants, the measures of risk (relative risk, odds ratio) provided are 
inconsistent from one study to another. Besides, the risk factors for CRBSI are still 
not clearly characterized in Malaysian setting, especially in subjects requiring 
haemodialysis via temporary CVC . Therefore, this research endeavour aims to shed 
some light on this scientific equipoise. Moreover, two additional benefits will be 
obtained from this research 
• The identification of CRBSI risk factors will assist in the prolongation of 
catheter survival and reduce other risks of early catheter failure. This will 
result in early interventions that will aid to prevent CRBSI at the earliest 
possible time. 
• The information on the types of isolated microorganisms that are responsible 
for CRBSI and their sensitivities to antibiotics will guide and steer the patient 
management towards a more rapid clinical intervention. 
 
  
 
 
 
 
 
 
 2.6 CONCEPTUAL FRAMEWORK 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1: Relationship between the risk factors and rates of CRBSI 
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 CHAPTER THREE 
OBJECTIVES 
 
3.1 GENERAL OBJECTIVE 
To determine the prevalence of catheter-related bloodstream infections (CRBSI) and 
its associated factors. 
3.2 SPECIFIC OBJECTIVES 
1) To estimate the prevalence of CRBSI in patients undergoing haemodialysis via 
temporary central venous catheter. 
2) To identify the main microorganism isolates involved in CRBSI and their patterns 
of antibiotics sensitivities. 
3) To determine the risk factors of CRBSI in patients with central venous catheter for 
haemodialysis. 
3.3 RESEARCH QUESTIONS 
1) What is the prevalence of CRBSI in patients who underwent haemodialysis via 
temporary central venous catheter at HUSM? 
2) What are the principal microorganisms isolated in patients with CRBSI and the 
patterns of antibiotics sensitivities at HUSM? 
3) What are the risk factors that are significantly associated with CRBSI in patients 
with central venous catheter for haemodialysis in HUSM? 
3.4 RESEARCH HYPOTHESES 
1,2) No research hypotheses are required for the first two objectives since they are 
readily answered by simple descriptive analyses. Therefore, no two competing 
hypotheses (null and alternative) are needed 
 3) Null hypothesis:. There is no specific factors associated with an increase risk of 
CRBSI among haemodialysis patient on temporary central venous catheter 
Alternative hypothesis:  There are certain factors which are associated with an 
increased risk of CRBSI among haemodialysis patient on temporary central venous 
catheter. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CHAPTER FOUR 
METHODOLOGY 
4.1 STUDY DESIGN 
This is a retrospective cohort study involving a review of medical records of 
Hospital USM CKD patients undergoing haemodialysis via central venous catheter 
acquired from HUSM registry. 
4.2 PERIOD OF DATA RECRUITMENT AND STUDY DURATION 
Data was collected on CKD patients with temporary central venous catheter for 
haemodialysis who were treated and recorded in the HUSM registry between 1st 
January 2013 and 31st October 2014. Therefore, the total duration of retrospective 
observation window is 22 months. 
The duration of research (proposal presentation, application for ethical approval, data 
collection, and thesis write-up) was from April 2014 until November 2014 (8 
months). 
4.3 STUDY AREA 
This study was conducted at Haemodialysis Unit of HUSM which is the tertiary 
centre of referral for CKD patients from the east coast states of Malaysia (Kelantan 
and Terengganu). On the average, CKD unit provides treatment for 200 to 300 
patients per annum. 
4.4 REFERENCE POPULATION 
All ESRD patients undergoing haemodialysis through central venous catheter in 
Kelantan and who are at risk of CRBSI. 
 
 
 4.5 SOURCE POPULATION 
All ESRD patients who required haemodialysis via central venous catheter at HUSM 
and were also at risk of CRBSI. 
4.6 SAMPLING FRAME 
ESRD patients with criteria as above and who also fulfilled inclusion and exclusion 
criteria. 
4.7 STUDY SUBJECTS 
ESRD patients who met the criteria as above and also consented to study 
participation. 
4.8 INCLUSION AND EXCLUSION CRITERIA 
4.8.1 Inclusion criteria 
i) Age at least or more than 18 years old at the time of catheter insertion 
ii) End stage renal failure patient that require haemodialysis via temporary central  
venous catheter. 
iii) No evidence of bacteraemia or sepsis at the time of catheter insertion 
4.8.2 Exclusion criteria 
i) Patients who were on antibiotics after the insertion of catheter and prior to the 
diagnosis of CRBSI. This is ascertained through documentation details in the 
medical records. 
ii) Pregnancy 
iii) Patients who require for new catheter reinsertion through a new or the same exit 
sites 
iv) Central catheter use for purposes other than haemodialysis 
 
4.9 SAMPLING METHOD 
Convenient sampling, a subset of non-probability sampling, was used due to the 
inadequate number of patients upon initial survey of the HUSM medical registry for 
ESRD patients undergoing haemodialysis at CKD unit. 
 
4.10 SAMPLE SIZE DETERMINATION 
Sample size was calculated using Power and Sample Size (PS) software version 
3.0.43 (Dupont and Plummer, Vanderbilt, USA; 2011). For objective 1 and 2, single 
proportion formula was used for calculating sample size. The formula is as follows: 
n= (1.96/ Δ)2 p(1-p). Precision (Δ) was chosen at 10% (0.10) to ensure the sample 
size calculated would be practical and achievable since higher precision (for 
instance, Δ=5%) would result in a very large sample size that is deemed impossible 
to achieve in this single-centre study. Therefore, the most optimal precision was 
selected to ensure the achievement the most optimal precision for objective 1 and 2. 
 
i) Objective 1: Prevalence of CRBSI 
For objective no 1, two approximate prevalence estimates of CRBSI in ESRD 
patients using temporary CVC for haemodialysis are provided by two different 
studies; a) Kim et al. (2006) – 11.7%,  and b) Bleyer et al. (2005) – 8.4%. Since the 
relationship between prevalence and incidence rate is described by the following 
formula (Fletcher et al. 2012): 
Prevalence rate ≈ [Incidence rate] x [Duration of the disease in a steady state], 
Therefore, the incidence rate as reported by Kim et al. (2006) and Bleyer et al. 
(2005) can be regarded as an approximate prevalence rate of CRBSI in ESRD 
patients who have non-tunneled CVC for haemodialysis since the duration of the 
disease is very short (CRBSI is a non-chronic disease). The estimate provided by 
Kim et al. (2006) was finally chosen as the more reliable one due to the larger 
sample size used for its estimation. 
n= (1.96/ Δ)2 p(1-p) 
Prevalence of CRBSI: 11.7% (Kim et al.  2006) 
Precision (Δ) = 0.05 
n = (1.96 /0.05)2 (0.117) (1-0.117) 
n = 40 subjects 
Drop out rate = 20% 
ntotal = 40 subjects + 20% = 44 subjects  
 
ii) Objective 2: Prevalence of main microorganism implicated for CRBSI 
S. aureus (both methicillin sensitive and resistant) is considered as the main 
microbial isolate in CRBSI cases. Four prevalence estimates were extracted from the 
previous literature for ESRD patients using temporary central venous catheter: 
a) Nabi et al. (2009): n= 7/11 (63.7%).  
b) Altaee et al. (2007): n =11/19 (57.8%) 
c) Kaze et al. (2014): n = 12/17 (70.6%) 
d) Nielsen et al. (1998): n= 14/25 (56%). This is the best estimate since it was based 
on the largest sample size.  
Nevertheless, since the estimates provided by a, b and c are quite close to each other, 
the prevalence estimate of S.aureus as the main microbial isolate found in CRBSI 
was hence decided to be approximately 60%. 
n= (1.96/ Δ)2 p(1-p) 
